Signature Estate & Investment Advisors LLC Raises Holdings in Boston Scientific Corporation $BSX

Posted by Brian Himes on May 22nd, 2026

Boston Scientific logo Signature Estate & Investment Advisors LLC lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 14.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,989 shares of the medical equipment provider’s stock after purchasing an additional 10,071 shares during the period. Signature Estate & Investment Advisors LLC’s holdings in Boston Scientific were worth $7,627,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BSX. Murphy & Mullick Capital Management Corp increased its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth about $26,000. United Community Bank increased its position in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Colonial Trust Co SC increased its position in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank increased its position in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Insider purchases are often viewed as a sign of management confidence in the company’s outlook and can support sentiment around the stock.
Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. The FRACTURE trial met all primary safety and effectiveness endpoints, which strengthens the case for a future regulatory submission and supports the company’s growth story in interventional cardiology.
Neutral Sentiment: Baird kept an Outperform rating on Boston Scientific, though it trimmed its price target to $75 from $78. That suggests the firm still sees upside, but the lower target may temper enthusiasm somewhat.
Negative Sentiment: Recent commentary also pointed to Boston Scientific having fallen on weak results, and the stock remains well below its longer-term moving averages. That indicates investors are still weighing execution concerns and broader pressure on the shares despite the upbeat insider and clinical developments.

Boston Scientific Stock Up 0.7%

BSX opened at $57.08 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $84.84 billion, a price-to-earnings ratio of 23.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. The business has a 50-day moving average of $62.21 and a two-hundred day moving average of $80.40. Boston Scientific Corporation has a 12 month low of $52.52 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Insider Activity

In related news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Habiger acquired 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 9,800 shares of company stock valued at $554,012 in the last ninety days. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of a number of recent research reports. Oppenheimer set a $90.00 price objective on Boston Scientific in a research report on Thursday, April 23rd. Citigroup dropped their price objective on Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. The Goldman Sachs Group lowered their target price on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Barclays lowered their target price on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research note on Thursday, April 23rd. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $92.71.

Read Our Latest Research Report on Boston Scientific

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.